comparemela.com

Page 3 - Clayton Professor News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Mutant Gene-Targeted Immunotherapy Approach Developed

share: This news release, issued by Johns Hopkins Medicine, describes a novel targeted immunotherapy approach. This new approach employs bispecific antibodies to treat cancer by eliciting a Tcell response against mutated p53. The researchers used the Highly Automated Macromolecular Crystallography (AMX) and Frontier Microfocusing Macromolecular Crystallography (FMX) beamlines to characterize the molecular structure of the proteins. AMX and FMX are beamlines at the National Synchrotron Light Source II (NSLS-II) a U.S. Department of Energy (DOE) Office of Science User Facility at Brookhaven National Laboratory. NSLS-II offers a comprehensive suite of life science research capabilities. Johns Hopkins media contacts: Amy Mone, 410-614-2915, amone@jhmi.edu, or Valerie Mehl, 410-614-2916, mehlva@jhmi.edu. Brookhaven Lab media contacts: Cara Laasch, 631-344-8458, laasch@bnl.gov or Peter Genzer, 631-344-3174, genzer@bnl.gov.

Researchers develop mutant gene-targeted immunotherapy approach to fight cancers

Researchers develop mutant gene-targeted immunotherapy approach to fight cancers A novel targeted immunotherapy approach developed by researchers at the Ludwig Center, the Lustgarten Laboratory, and Bloomberg~Kimmel Institute for Cancer Immunotherapy at the Johns Hopkins Kimmel Cancer Center employs new antibodies against genetically altered proteins to target cancers. The researchers targeted their immunotherapy approach to alterations in the common cancer-related p53 tumor suppressor gene, the RAS tumor-promoting oncogene or T-cell receptor genes. They also tested the therapy on cancer cells in the laboratory and in animal tumor models. Their findings are reported in three related studies published March 1 in Science Immunology,

Mutant gene-targeted immunotherapy approach developed

Two of the three research studies led by Jacqueline Douglass, M.D., Ph.D. candidate at the Johns Hopkins University School of Medicine and Emily Han-Chung Hsiue, M.D., Ph.D., postdoctoral fellow at Johns Hopkins report on a precision medicine immunotherapy approach that specifically kills cancer cells by targeting mutant protein fragments presented as antigens on the cancer cell surface. Although common across cancer types, p53 mutations have not been successfully targeted with drugs. Genetic alterations in tumor suppressor genes often resulted in their functional inactivation. Traditional drugs are aimed at inhibiting proteins. Inhibiting an already inactivated tumor suppressor gene protein in cancer cells, therefore, is not a feasible approach, says Hsiue, lead author on the

【全部500円】『イナズマイレブン』や『妖怪ウォッチ』などレベルファイブの3DSソフトが500円に。本日2/3よりセール開催

【全部500円】『イナズマイレブン』や『妖怪ウォッチ』などレベルファイブの3DSソフトが500円に。本日2/3よりセール開催
famitsu.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from famitsu.com Daily Mail and Mail on Sunday newspapers.

『謎解きゲーム』でオススメ教えてください : ゲームだらだら速報

『謎解きゲーム』でオススメ教えてください : ゲームだらだら速報
gamedaradara.doorblog.jp - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from gamedaradara.doorblog.jp Daily Mail and Mail on Sunday newspapers.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.